EXPERIENCE OF THE TYPE A BOTULINUM TOXIN TYPE (ONABOTULINUMTOXINA) DRUG IN TREATMENT OF CEREBRAL PALSY PATIENTS

Abstract

Injections of botulinum toxin type A (BTA) are regarded as one of the basic methods to treat cerebral palsy (CP). The article discusses issues unique mechanism of action of botulinum toxin type A injections, double sensomotor mechanism of action of the drug OnabotulinumtoxinA, noninterchangeability of BTA drugs, evidence of efficacy and safety of the use of BTA for children with cerebral palsy, accuracy control of BTA injections, selection of muscle targets, assess the effectiveness of botulinum toxin therapy, etc. To the therapy used in cases where the manifestations of spasticity in cerebral palsy become significant and negative influence on the functional activity and motor development of the child. Injections of botulinum toxin type A in cerebral palsy are usually applied from the age of 2 years, and this treatment is indicated for 50-75% of patients depending on the level of motor abilities by GMFCS scale. If this treatment is not used in presence of indications, it is possible to say that the treatment is carried out not in full and the patient is deprived of the proven effective therapeutic approach.

Keywords

• botulinum toxin type a
• onabotulinumtoxina
• pediatric cerebral palsy
• spasticity
• ashworth scale
• tardieu scale
• global motor function scale
• equinus foot position
• bta mechanism of action
• noninterchangeability of botulinum toxin type a injections
• accuracy control of bta injections
• assessment of therapy effectiveness